体外冲击波治疗佩罗尼病的治疗作用更新推荐:系统评价与Meta分析
该系统评价与Meta分析纳入4项RCT,共151例接受体外冲击波治疗(ESWT)和150例对照,评估ESWT对佩罗尼病(PD)的疗效。结果显示,ESWT可显著缩小斑块(OR 2.59,95%CI 1.15~5.85,P=0.02)并缓解疼痛(MD -1.55,95%CI -2.46~-0.64,P=0.0008);但对阴茎弯曲(OR 1.93,95%CI 0.87~4.26,P=0.11)和性功能改善(MD 2.6,95%CI -1.63~6.83,P=0.23)无显著效果,两组并发症发生率也无显著差异(OR 2.94,95%CI 0.66~13.03,P=0.16)。作者认为,ESWT可考虑作为安全的短期治疗,长期疗效有待讨论。
要点
- 在4项RCT共151例ESWT组与150例对照组中,ESWT显著缩小斑块(OR 2.59,95%CI 1.15~5.85,P=0.02)。
- ESWT显著缓解疼痛(MD -1.55,95%CI -2.46~-0.64,P=0.0008)。
- ESWT对阴茎弯曲无显著改善(OR 1.93,95%CI 0.87~4.26,P=0.11)。
- ESWT对性功能无显著改善(MD 2.6,95%CI -1.63~6.83,P=0.23)。
- 两组并发症发生率无显著差异(OR 2.94,95%CI 0.66~13.03,P=0.16)。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入4项RCT,ESWT组151例、对照组150例,检索PubMed、CENTRAL和Embase自2000年1月1日至2022年12月31日的文献。
- ESWT显著缩小斑块(OR 2.59,95%CI 1.15~5.85,P=0.02)。
- ESWT显著缓解疼痛(MD -1.55,95%CI -2.46~-0.64,P=0.0008)。
- ESWT对阴茎弯曲无显著改善(OR 1.93,95%CI 0.87~4.26,P=0.11)。
- ESWT对性功能无显著改善(MD 2.6,95%CI -1.63~6.83,P=0.23)。
- 两组并发症发生率无显著差异(OR 2.94,95%CI 0.66~13.03,P=0.16)。
- 偏倚风险评估采用Cochrane协作网ROB-2,结果为低偏倚风险;本文件采用PRISMA 2020指南进行定量与定性合成。
证据类型、等级与局限
- 证据类型为系统评价与Meta分析,仅纳入RCT,偏倚风险评估采用ROB-2,结果为低偏倚风险。
- 局限:纳入研究数量太少,部分实验结局缺失,结局表达不统一。
- 作者结论认为ESWT可作为安全的短期治疗,长期疗效仍有待讨论。
对床旁实践的改变
- 作者认为,对佩罗尼病,ESWT可考虑作为安全的短期治疗,可缩小斑块并缓解疼痛,但不能改善阴茎弯曲和性功能。
- 作者认为ESWT的长期疗效仍有待讨论。
指南或共识出处
- PROSPERO注册号CRD42023436744
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The therapeutic role of extracorporeal shockwave therapy (ESWT) for Peyronie's disease (PD) has been controversial in a long term. We aimed to further evaluate the therapeutic effect of ESWT for PD on the basis of available high-quality studies.
METHODS: The PubMed, CENTRAL and Embase databases were searched for articles published from January 1st, 2000 to December 31, 2022. Only randomized controlled trials (RCTs) using ESWT to treat PD were included. Meta-analysis and forest plots were carried out using Review Manager 5.4.1 software, and outcomes were reviewed by 2 authors independently. Using the Risk of Bias assessment form (ROB-2) by Cochrane Collaboration for quality assessment. PRISMA 2020 guidelines were used in this article to achieve the quantitative and qualitative synthesis of data.
RESULTS: A total of four RCTs were included. 151 patients in the ESWT group and 150 patients in the control group. The meta-analysis results showed that ESWT could significantly reduce plaque size (OR 2.59, 95%CI 1.15 to 5.85, P = 0.02) and relieve pain (MD -1.55, 95%CI -2.46 to -0.64, P = 0.0008); but it has no significant effect on reducing the penile curvature (OR 1.93, 95%CI 0.87-4.26, P = 0.11) and improving sexual function (MD 2.6, 95%CI -1.63 to 6.83, P = 0.23), there is also no significant difference in complication rates between groups (OR 2.94, 95%CI 0.66 to 13.03, P = 0.16). The risk of bias of results is low. The limitations of this study are that the number of included studies is too small, some experimental outcomes are missing, and the expression of outcomes is not unified.
CONCLUSIONS: For PD, ESWT can be considered as a safe short-term treatment, which can reduce plaque size and relieve pain, but cannot improve penile curvature and sexual function. Its long-term efficacy remains to be discussed.
REGISTRATION NUMBER: PROSPERO (ID: CRD42023436744).
参考来源
- Wang X, Liu H, Tang G, et al. Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis. BMC Urol. 2023. PMID: 37700253. doi:10.1186/s12894-023-01320-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。